Cost-effectiveness of end-game strategies against sleeping sickness across the Democratic Republic of Congo

  1. Marina Antillon
  2. Ching-I Huang
  3. Samuel A. Sutherland
  4. Ronald E. Crump
  5. Paul E. Brown
  6. Paul R. Bessell
  7. Emily H. Crowley
  8. Rian Snijders
  9. Andrew Hope
  10. Iñaki Tirados
  11. Sophie Dunkley
  12. Paul Verlé
  13. Junior Lebuki
  14. Chansy Shampa
  15. Erick Mwamba Miaka
  16. Fabrizio Tediosi
  17. Kat S. Rock

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

Background

Gambiense human African trypanosomiasis (gHAT) is marked for elimination of transmission (EoT) by 2030. We examined the cost-effectiveness (CE) of EoT in the Democratic Republic of Congo, which has the highest global gHAT burden.

Methods

In 165 health zones (HZs), we modelled the transmission dynamics, health outcomes, and economic costs of six strategies during 2026–40, including the cessation of activities after cases reported reach zero. Uncertainty in CE was assessed within the net monetary framework, which presents the optimal strategies at a range of willingness- to-pay (WTP) values, denominated in costs per disability-adjusted life-year averted. We assessed the optimal strategy for CE and EoT in each health zone separately, but we present results by health zone as well as aggregated by coordination and for the whole country.

Results

Status quo strategies, CE strategies (WTP=$500), and strategies with a high probability of EoT by 2030 are predicted to yield EoT by 2030 in 118 HZs, 123 HZs, and 134 HZs respectively, at a cost by 2040 of $67.8M [95% PI: $36.7M–113M], $93.3M [95% PI: $51.6M–153M], $185M [95% PI: $111M–309M]. A more lenient timeline of EoT by 2040 could lead to EoT in 152 HZs at a cost of $158M [95% PI: $91.6-265M], leaving 13 HZs shy of the goal. Costs would have to be front-loaded; in 2026, while status quo strategies would cost $8.75M [95% PI: $7.01M–11.2M], elimination strategies would cost $27.0 [95% PI: $21.0M–35.2M]. Investing in EoT by 2030 is predicted to reduce 68% of gHAT deaths from 7979 [95% PI: 770–27,868] with status quo strategies to 2576 [95% PI: 255–9133].

Conclusions

The current arsenal of tools could make considerable progress to maximise the probability of EoT by 2030, but select health zones are facing a low probability of EoT even with more ambitious strategies. Investments need to be front-loaded, but we would witness considerable returns on investment by 2040.

Article activity feed

  1. Rapid Reviews Infectious Diseases

    Sigal Maya

    Review 2: "Cost-effectiveness of End-game Strategies Against Sleeping Sickness across the Democratic Republic of Congo"

    Reviewers found the methodology used in this analysis to be robust and reliable in general though one reviewer had concerns that limitations were not discussed in enough detail. 

  2. Rapid Reviews Infectious Diseases

    David R Holtgrave

    Review 1: "Cost-effectiveness of End-game Strategies Against Sleeping Sickness across the Democratic Republic of Congo"

    Reviewers found the methodology used in this analysis to be robust and reliable in general though one reviewer had concerns that limitations were not discussed in enough detail. 

  5. Version published to 10.1101/2024.03.29.24305066 on medRxiv